FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pulmonology, and can be used for diagnosing bronchial asthma in a patient by determining concentration of asymmetric dimethylarginine in blood plasma. Concentration of asymmetric dimethylarginine in blood plasma is measured by enzyme immunoassay and patient’s body mass index. Diagnostic coefficient K is calculated by formula: K = Y – (195.45 – 5.11 × X), where Y is asymmetric dimethylarginine, ng/ml, and X is BMI, kg/m2. If K is less than 3.126, the patient is diagnosed with bronchial asthma.
EFFECT: method enables the accessible and effective diagnosis of bronchial asthma by determining the concentration of asymmetric dimethylarginine in the blood and the patient’s body mass index.
1 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING BRONCHIAL ASTHMA IN PATIENT BY DETERMINING CONCENTRATION OF ARGINASE-1 IN BLOOD PLASMA | 2024 |
|
RU2825347C1 |
| METHOD OF DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION | 2023 |
|
RU2814392C1 |
| METHOD FOR DIAGNOSING EARLY CHRONIC RENAL DISEASE IN CHILDREN | 2020 |
|
RU2753581C1 |
| METHOD FOR DIAGNOSIS OF CLINICAL COURSE OF "ASYMPTOMATIC" CAROTID ATHEROSCLEROSIS | 2015 |
|
RU2592237C1 |
| METHOD FOR PREDICTING EXACERBATIONS OF BRONCHIAL ASTHMA FOR THE NEAR FIRST YEAR IN PATIENTS WITH CONCOMINANT OBESITY | 2018 |
|
RU2655829C1 |
| METHOD FOR DETECTING THE RISK OF DEVELOPING SYMPTOMATIC CAROTID STENOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2779063C1 |
| METHOD OF ASSESSING PRESENCE OF DYSFUNCTION OF SMALL AIRWAYS IN PATIENTS WITH MILD BRONCHIAL ASTHMA | 2022 |
|
RU2806491C1 |
| METHOD FOR ASSESSING THE SEVERITY OF BRONCHIAL ASTHMA EXACERBATION USING AN INTEGRAL INDICATOR | 2021 |
|
RU2765432C1 |
| METHOD FOR DIAGNOSING INSULIN RESISTANCE IN PATIENTS WITH TYPE 1 DIABETES MELLITUS | 2024 |
|
RU2825046C1 |
| METHOD FOR PREDICTING THE RISK OF LIVER FIBROSIS IN PATIENTS WITH OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE | 2022 |
|
RU2794862C1 |
